Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction
- Details
- Category: Novo Nordisk
Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia® plus metformin at 52 weeks.
ONGLYZA (saxagliptin) with Metformin as Initial Combination Therapy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced results up to 76-weeks from a Phase 3 study of ONGLYZA™ (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naïve adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.
Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA).
AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214
- Details
- Category: AstraZeneca
AstraZeneca and Targacept, Inc., announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.
34 Teachers and Schools Across North America Receive $10,000 Amgen Award
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence.
New SIMPONI (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis
- Details
- Category: Merck
Findings from an open-label, uncontrolled long-term extension of a Phase 3 registration trial demonstrated efficacy of SIMPONI in patients with moderately to severely active rheumatoid arthritis despite methotrexate therapy at two years.
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
- Details
- Category: Novartis
Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
More Pharma News ...
- RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
- Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance
- Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix
- Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients
- Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
- Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL
- Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint